OR WAIT null SECS
© 2022 MJH Life Sciences and Optometry Times. All rights reserved.
© 2022 MJH Life Sciences™ and Optometry Times. All rights reserved.
May 17, 2022
The company, formerly known as Clover Therapeutics, intends to use the funding to advance two lead drug candidates that target molecularly-defined AMD patient subtypes.
May 12, 2022
The company's technology allows for ECPs to detect, monitor, and treat AMD 3 years before clinical diagnosis.
A look at the latest developments in retinal disease, including clinical trials and advanced therapies.
May 05, 2022
New detailed, longer-term findings were presented at the 2022 ARVO meeting.
April 27, 2022
Diagnosis highlights overlooked treatments for this disease
April 21, 2022
Gifted by philanthropist James Grosfeld, the money will fund the launching of a pioneering research initiative as one of the largest investments of resources in the United States.
April 18, 2022
Researchers found that patients with nAMD lost vision as a result of the lockdown and reduced number of treatments during the COVID-19 pandemic.
April 07, 2022
Elevatum was created as a phase 4, multicenter, open-label, single-arm trial to specifically study Vabysmo (faricimab-svoa) in these underrepresented populations.
April 04, 2022
New research finds a drug used to treat alcohol use disorder could be a game-changer in restoring vision for patients with progressive blinding disorders.
January 28, 2022
Faricimab is now the first and only FDA-approved drug to target two distinct pathways known to cause retinal disease that may lead to vision loss.
Battery-free, smart contact lens delivers glaucoma drugs
Aerie doses first patient in phase 3 DED treatment study
Eyeglasses target myopia prevention with artificial light
Research to Prevent Blindness, Aerie partner on glaucoma research grant